
NASDAQHealthcareMedical - Devices
ข้อมูลล่าสุด
US$0.2297
−US$0.0117 · -4.85%
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
ราคาปิดก่อนหน้า
US$0.2297
−US$0.0117 · -4.85%
หลังปิดตลาด
US$0.2226
−US$0.0071 · -3.09%
9 ต.ค. 19:47 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
ช่วงราคารายวัน
ปัจจุบัน US$0.2297
ช่วง 52 สัปดาห์
ปัจจุบัน US$0.2297
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ขาย
มูลค่า
70
ต่ำกว่ามูลค่า
ความเชื่อมั่น
46
ผสม
ความเสี่ยง
75
ความเสี่ยงสูง
โมเมนตัม
17
ขาลงรุนแรง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
ช่วงราคารายวัน
ปัจจุบัน US$0.2297
ช่วง 52 สัปดาห์
ปัจจุบัน US$0.2297
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2026 | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 |
|---|---|---|---|---|---|
| รายได้ | 401.95M USD | 458.51M USD | 446.55M USD | 447.61M USD | 429.91M USD |
| ต้นทุนสินค้าขาย | 290.49M USD | 311.54M USD | 303.63M USD | 293.65M USD | 269.95M USD |
| กำไรขั้นต้น | 111.45M USD | 146.97M USD | 142.92M USD | 153.96M USD | 159.96M USD |
| การวิจัยและพัฒนา | 37.75M USD | 47.94M USD | 49.73M USD | 57.13M USD | 57.75M USD |
| การขาย ทั่วไป และธุรการ | 83.97M USD | 91.19M USD | 92.69M USD | 94.45M USD | 94.06M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 137.9M USD | 139.13M USD | 142.42M USD | 151.58M USD | 151.81M USD |
| รายได้ดอกเบี้ย | — | 1.19M USD | — | — | — |
| ดอกเบี้ยจ่าย | 35.31M USD | 12.95M USD | 11.62M USD | 10.63M USD | 8.13M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 7.94M USD | 6.15M USD | 5.91M USD | 4.53M USD | 5.51M USD |
| รายได้จากการดำเนินงาน | −26.44M USD | 7.84M USD | 504K USD | 2.38M USD | 8.15M USD |
| รายได้สุทธิ | −49.19M USD | −1.59M USD | −15.55M USD | −9.28M USD | −5.35M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 10 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$2.00
โอกาสปรับขึ้น 770.70%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI821.21K0.00%2.3T USD0.03%US$381.94+0.63%
Fidelity Enhanced Small Cap ETFFESM346.09K0.01%6.41B USD0.28%US$45.46+0.46%
Vanguard Extended Market ETFVXF312.99K0.00%95.4B USD0.05%US$235+0.80%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM29.86K0.00%688.81M USD0.89%US$57.70+0.92%
Invesco RAFI US 1500 Small-Mid ETFPRFZ27.83K0.00%2.65B USD0.36%US$53.16+0.64%
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM
Invesco RAFI US 1500 Small-Mid ETFPRFZเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน